Skip to main content
Erschienen in: Supportive Care in Cancer 9/2008

01.09.2008 | Original Article

Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders

verfasst von: Hans Jürgen Dornbusch, Volker Strenger, Petra Sovinz, Herwig Lackner, Wolfgang Schwinger, Reinhold Kerbl, Christian Urban

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Procalcitonin (PCT) is considered a sensitive and specific diagnostic and prognostic marker of systemic bacterial infection, but its value is questionable in certain clinical conditions, particularly in hemato-oncological patients.

Materials and methods

We analyzed PCT and C-reactive protein (CRP) levels in 56 patients of a pediatric hematology–oncology unit during 110 consecutive non-infectious febrile episodes related to administration of T-cell antibodies (group A; n = 22), alemtuzumab (monoclonal CD52 antibody, CAMPATH-1H/group B; n = 8), interleukin-2 (IL-2/group C; n = 41), prophylactic donor granulocyte transfusions (group D; n = 9), or to acute graft-versus-host disease (aGvHD/group E; n = 10) and compared the results with 20 episodes of Gram-negative sepsis (group F).

Main results

In the majority of the non-infectious episodes PCT and CRP increased to serum levels statistically indistinguishable from Gram-negative sepsis. Median peak levels of PCT (normal < 0.5 ng/ml)/CRP (normal < 8 mg/l) for groups A–F were 4.34/59.0 (A), 10.14/93.5 (B), 1.11/175.0 (C), 1.43/164 (D), 0.96/34.0 (E), and 8.14 ng/ml /126.0 mg/l (F). Highest single levels were observed in groups A and F.

Conclusions

PCT and CRP are of limited value as diagnostic markers of sepsis during T-cell-directed immunomodulatory treatment, granulocyte support, or acute GvHD.
Literatur
1.
Zurück zum Zitat Aouifi A, Piriou V, Bastien O, Blanc P, Bouvier H, Evans R, Celard M, Vandenesch F, Rousson R, Lehot JJ (2000) Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 28(9):3171–3176PubMedCrossRef Aouifi A, Piriou V, Bastien O, Blanc P, Bouvier H, Evans R, Celard M, Vandenesch F, Rousson R, Lehot JJ (2000) Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 28(9):3171–3176PubMedCrossRef
2.
Zurück zum Zitat Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE (2000) Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 7(6):889–892PubMedCrossRef Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE (2000) Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 7(6):889–892PubMedCrossRef
3.
Zurück zum Zitat Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409):600–607PubMedCrossRef Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409):600–607PubMedCrossRef
4.
Zurück zum Zitat Christ-Crain M, Müller B (2005) Procalcitonin in bacterial infections—hype, hope, more or less. Swiss Med Wkly 135:451–460PubMed Christ-Crain M, Müller B (2005) Procalcitonin in bacterial infections—hype, hope, more or less. Swiss Med Wkly 135:451–460PubMed
5.
Zurück zum Zitat Dehne MG, Sablotzki A, Hoffmann A, Muhling J, Dietrich FE, Hempelmann G (2002) Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns 28(6):535–542PubMedCrossRef Dehne MG, Sablotzki A, Hoffmann A, Muhling J, Dietrich FE, Hempelmann G (2002) Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns 28(6):535–542PubMedCrossRef
6.
Zurück zum Zitat Dornbusch HJ, Kerbl R, Lackner H, Preisegger KH, Schwinger W, Berghold A, Urban C (2000) Procalcitonin and C-reactive protein levels at the time of engraftment after stem cell transplantation. Acta Chir Austriaca 32(Suppl 170):37 Dornbusch HJ, Kerbl R, Lackner H, Preisegger KH, Schwinger W, Berghold A, Urban C (2000) Procalcitonin and C-reactive protein levels at the time of engraftment after stem cell transplantation. Acta Chir Austriaca 32(Suppl 170):37
7.
Zurück zum Zitat Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C (2003) Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant 32:941–945PubMedCrossRef Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C (2003) Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant 32:941–945PubMedCrossRef
8.
Zurück zum Zitat Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C (2005) Procalcitonin—a marker of invasive fungal infection. Support Care Cancer 13:343–346PubMedCrossRef Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C (2005) Procalcitonin—a marker of invasive fungal infection. Support Care Cancer 13:343–346PubMedCrossRef
9.
Zurück zum Zitat Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin-6, interleukin-8, soluble interleukin-2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111(4):1093–102PubMedCrossRef Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin-6, interleukin-8, soluble interleukin-2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111(4):1093–102PubMedCrossRef
10.
Zurück zum Zitat Hansson LO, Lindquist L (1997) C-reactive protein: its role in the diagnosis and follow-up of infectious diseases. Curr Opin Infect Dis 10:196–201CrossRef Hansson LO, Lindquist L (1997) C-reactive protein: its role in the diagnosis and follow-up of infectious diseases. Curr Opin Infect Dis 10:196–201CrossRef
11.
Zurück zum Zitat Hayden WR (1994) Sepsis terminology in pediatrics. J Pediatr 124(4):657–658PubMed Hayden WR (1994) Sepsis terminology in pediatrics. J Pediatr 124(4):657–658PubMed
12.
Zurück zum Zitat Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100(11):2462–2469PubMedCrossRef Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100(11):2462–2469PubMedCrossRef
13.
Zurück zum Zitat Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin lymphoma. Leuk Lymphoma 31:351–357PubMed Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin lymphoma. Leuk Lymphoma 31:351–357PubMed
14.
Zurück zum Zitat Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Boehme A, Hoelzer D, Martin H (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84(11):734–741 (electronically prepublished 11 Jun 2005)PubMedCrossRef Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Boehme A, Hoelzer D, Martin H (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84(11):734–741 (electronically prepublished 11 Jun 2005)PubMedCrossRef
15.
Zurück zum Zitat Müller B, White J, Nylen E, Snider R, Becker K, Habener J (2001) Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86:396–404PubMedCrossRef Müller B, White J, Nylen E, Snider R, Becker K, Habener J (2001) Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86:396–404PubMedCrossRef
16.
Zurück zum Zitat Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, Kimura H, Morikawa A (2004) Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 48(2):199–205PubMedCrossRef Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, Kimura H, Morikawa A (2004) Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 48(2):199–205PubMedCrossRef
17.
Zurück zum Zitat Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating course in patients with febrile neutropenia. Eur J Haematol 74(4):297–303PubMedCrossRef Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating course in patients with febrile neutropenia. Eur J Haematol 74(4):297–303PubMedCrossRef
18.
Zurück zum Zitat Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ, Holler E (2006) Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 76(2):93–101PubMedCrossRef Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ, Holler E (2006) Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 76(2):93–101PubMedCrossRef
19.
Zurück zum Zitat Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant 15(6):825–828PubMed Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant 15(6):825–828PubMed
20.
Zurück zum Zitat Sabat R, Hoflich C, Docke WD, Oppert M, Kern F, Windrich B, Rosenberger C, Kaden J, Volk HD, Reinke P (2001) Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 27(6):987–991PubMedCrossRef Sabat R, Hoflich C, Docke WD, Oppert M, Kern F, Windrich B, Rosenberger C, Kaden J, Volk HD, Reinke P (2001) Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 27(6):987–991PubMedCrossRef
21.
Zurück zum Zitat Saijo Y, Kiyota N, Kawasaki Y, Miyazaki Y, Kashimura J, Fukuda M, Kishi R (2004) Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab 6(4):249–258PubMedCrossRef Saijo Y, Kiyota N, Kawasaki Y, Miyazaki Y, Kashimura J, Fukuda M, Kishi R (2004) Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab 6(4):249–258PubMedCrossRef
22.
Zurück zum Zitat Schwinger W, Klass V, Benesch M, Dornbusch HJ, Sovinz P, Moser A, Schwanzer G, Urban C (2005) Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 16:1199–1206PubMedCrossRef Schwinger W, Klass V, Benesch M, Dornbusch HJ, Sovinz P, Moser A, Schwanzer G, Urban C (2005) Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 16:1199–1206PubMedCrossRef
23.
Zurück zum Zitat Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef
24.
Zurück zum Zitat Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113PubMedCrossRef
25.
Zurück zum Zitat Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O (2000) Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 19(7):598–602PubMedCrossRef Toikka P, Irjala K, Juven T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O (2000) Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 19(7):598–602PubMedCrossRef
26.
Zurück zum Zitat Van Rossum AMC, Wulkan RW, Oudesluys-Murphy AM (2004) Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 4:620–630PubMedCrossRef Van Rossum AMC, Wulkan RW, Oudesluys-Murphy AM (2004) Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 4:620–630PubMedCrossRef
27.
Zurück zum Zitat Wing MG, Thibault M, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FCgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819–2826PubMedCrossRef Wing MG, Thibault M, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FCgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819–2826PubMedCrossRef
28.
Zurück zum Zitat Yip HK, Hang CL, Fang CY, Hsieh YK, Yang CH, Hung WC, Wu CJ (2005) Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 127(3):803–808PubMedCrossRef Yip HK, Hang CL, Fang CY, Hsieh YK, Yang CH, Hung WC, Wu CJ (2005) Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 127(3):803–808PubMedCrossRef
Metadaten
Titel
Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders
verfasst von
Hans Jürgen Dornbusch
Volker Strenger
Petra Sovinz
Herwig Lackner
Wolfgang Schwinger
Reinhold Kerbl
Christian Urban
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0381-1

Weitere Artikel der Ausgabe 9/2008

Supportive Care in Cancer 9/2008 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.